))
Ep. 56 - BIO’s John Crowley on the Biosecure Act
Manage episode 416017393 series 3571902
Inhoud geleverd door BioCentury. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door BioCentury of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.
BIO CEO John Crowley believes that biotech is part of a “great global rivalry” between the U.S. and China. The role of biotech in determining the outcome of this rivalry, and a belief in the need for reducing U.S. reliance on Chinese biotech companies, led BIO to reverse its opposition to the Biosecure Act. Crowley acknowledges concerns that the enactment of the bill in its current form would create serious disruptions in drug development. By accepting its overall goals and engaging with Congress, BIO will have opportunities to persuade negotiate changes that will mitigate its negative consequences for biopharma companies and patients, Crowley told BioCentury Washington Editor Steve Usdin in this episode of #TheBioCenturyShow.
View full story: https://www.biocentury.com/article/651990
#biotech #biopharma #pharma #biosecureact #lifescience
00:00 - Intro
03:57 - Decoupling from China
11:33 - Biosecure Act
15:48 - Rare Diseases at FDA
25:02 - Fly-outs and Big Ideas
28:05 - Changing the Narrative
Hoofdstukken
1. Introduction (00:00:00)
2. Decoupling from China (00:03:57)
3. Biosecure Act (00:11:33)
4. Rare Diseases at FDA (00:15:48)
5. Fly-outs and Big Ideas (00:25:02)
6. Changing the Narrative (00:28:05)
22 afleveringen
Delen
